According to the results of a newly published study, “psilocybin is highly effective in reducing depressive symptoms severity” among patients with major depressive disorder and treatment-resistant depression.
Published in the journal Brain Sciences, the study is titled Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials. It was conducted by researchers from Sigmund Freud University of Milan, Vita-Salute San Raffaele University and Vita-Salute San Raffaele University, all in Italy
“Current pharmacological treatments for major depressive disorder (MDD) are often only partially effective, with many patients experiencing no significant benefit, leading to treatment-resistant depression (TRD)”, states the study. “Psilocybin, a classical serotonergic psychedelic, has emerged as a notable emerging treatment for such disorders.”
Continue reading